alcaftadine

al-KAFF-ta-deen

Therapeutic Classification: ocular agents

Pharmacologic Classification: antihistamines

REMS

Antagonizes the effects of histamine at H₁ receptor sites in the eye; does not bind or inactivate histamine.
Also decreases histamine release from mast cells.

Therapeutic effects:

Absorption: Minimal systemic absorption follows ophthalmic use.

Distribution: Unknown.

Metabolism/Excretion: Some conversion to an active carboxylic acid metabolite, which is excreted unchanged by the kidneys.

Half-Life: 2 hr (carboxylic acid metabolite).

(antihistaminic effect)

ROUTE	ONSET	PEAK	DURATION
ophth	3 min	unknown	16 hr

Contraindicated in:

Use Cautiously in:

EENT: eye irritation/burning/stinging/itching, nasopharyngitis

Neuro: headache

Drug-drug:

Assess signs and symptoms of allergic conjunctivitis (redness, itching, watering) periodically during therapy.

Instill 1 drop into affected eyes twice daily. See Medication Administration Techniques for administration guidelines.

Instruct patient to instill alcaftadine drops as directed. Do not touch dropper to eye or to any surface.
Advise patient to remove contact lens prior to instillation. Do not use alcaftadine for treatment of irritation related to contact lens. Do not wear contact lens if eyes are red. Contact lens may be reinserted 10 min following instillation.
Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Lastacaft